Compare ARK Autonomous Technology & Robotics ETF (ARKQ) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Autonomous Technology & Robotics ETF vs Crispr Therapeutics AG — how do they compare? ARK Autonomous Technology & Robotics ETF trades at $128.4, while Crispr Therapeutics AG trades at $53.88 (market cap $5.23B). The key difference: ARK Autonomous Technology & Robotics ETF is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| ARKQ | CRSP | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $143.82 | $76.78 |
52-Week Low | $95.28 | $44.34 |
Market Cap | — | $5.23B |
Enterprise Value | — | $3.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKQ trades at $127.85, up 3.77% today, with a bullish technical signal from moving averages but a neutral reading from oscillators. The ETF focuses on autonomous technology and robotics, with recent news highlighting its exposure to SpaceX and defense stocks. Support and resistance levels indicate key price zones for near-term movement.
The outlook for ARKQ is supported by long-term themes in AI and robotics, though high RSI levels suggest caution. Risks include sector volatility and reliance on disruptive tech stocks. Analyst sentiment is mixed, with some recommending accumulation during dips for growth-oriented investors.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Autonomous Technology & Robotics ETF
ARKQ is an actively managed ETF that invests in autonomous technology and robotics. It focuses on disruptive innovations like autonomous mobility, electric vehicles, 3D printing, and energy storage, with holdings such as Tesla and Teradyne.
Read more on ARKQ →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
